Katie Kortbein

Instead of copying other OECD countries in a “reference-price-race-to-the-bottom,” U.S. policy should instead encourage peer countries to appropriately value innovative medicines.

The FDA is considering allowing seven unapproved peptides—substantially sourced through a Chinese gray market—to be used by U.S. compounding pharmacies, despite its own scientists warning against it. Approving them would legitimize unvetted foreign suppliers and undermine evidence-based drug regulation.